Active Trials of the GCLLSG
First-Line Therapies for CLL
- CLL11
- Three arm randomized, phase III
study to compare the efficacy and safety of
• RO5072759 (GA101) + Chlorambucil (GClb),
• Rituximab + Chlorambucil (RClb) oder
• Chlorambucil alone (Clb)
- in previously untreated CLL patients
with comorbidities.
- Pivotal trial for the novel, monoclonal, humanized anti-CD20 antibody RO5072759 (GA101).
- » more
Therapies for relapsed/refractory CLL
- CLL2P
- A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia
- » more
Transplantation Trials
Currently no recruiting transplantation trials
Trials for T-PLL
- T-PLL2
-
- Phase II trial for the assessment of feasibility, safety and efficacy of the combined immunochemotherapy with FMC-Alemtuzumab followed by Alemtuzumab-maintenance therapy in untreated or pretreated patients with T-PLL
- » more
